GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sutro Biopharma Inc (FRA:S09) » Definitions » EBITDA Margin %

Sutro Biopharma (FRA:S09) EBITDA Margin % : -458.63% (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Sutro Biopharma EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sutro Biopharma's EBITDA for the three months ended in Sep. 2024 was €-35.2 Mil. Sutro Biopharma's Revenue for the three months ended in Sep. 2024 was €7.7 Mil. Therefore, Sutro Biopharma's EBITDA margin for the quarter that ended in Sep. 2024 was -458.63%.


Sutro Biopharma EBITDA Margin % Historical Data

The historical data trend for Sutro Biopharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sutro Biopharma EBITDA Margin % Chart

Sutro Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial -109.08 -55.60 -157.65 -158.87 -37.75

Sutro Biopharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -218.80 50.42 -361.75 -144.62 -458.63

Competitive Comparison of Sutro Biopharma's EBITDA Margin %

For the Biotechnology subindustry, Sutro Biopharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sutro Biopharma's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sutro Biopharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Sutro Biopharma's EBITDA Margin % falls into.



Sutro Biopharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Sutro Biopharma's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-53.218/140.971
=-37.75 %

Sutro Biopharma's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-35.209/7.677
=-458.63 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sutro Biopharma  (FRA:S09) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Sutro Biopharma EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Sutro Biopharma's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sutro Biopharma Business Description

Traded in Other Exchanges
Address
111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Sutro Biopharma Headlines

No Headlines